With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Pharmaceutical companies have already raised the price of over 800 brand-name prescription drugs this year. Nearly all the ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...